

Ring, Ring—Got My Implant?

Real World Access to the Etongestrel Implant Among Family Pact Providers: A Secret Shopper Study

Avery Lahodny OMS-III, Anita Nelson M.D.

Western University of Health Sciences College of Osteopathic Medicine of The Pacific Pomona, CA


INTRODUCTION

- California's Family Planning, Access, Care, and Treatment (Family PACT) program provides all forms of contraception free of charge to all uninsured California residents who fall below 200% of the federal poverty line¹.
- Even with funding, patients may not be able to find a participating provider in an accessible location, obtain accurate information, or receive their desired contraceptive method without additional visits or referrals^{2,5}.
- These barriers may be particularly consequential for adolescents and patients in geographically dispersed, medically underserved areas.
- San Bernardino and Riverside Counties span more than 27,000 square miles and 52% of the population are eligible reproductive age females^{2,5}.
- Although the etonogestrel implant is a highly effective, user independent contraceptive method, it does require a face to face meeting with a provider for insertion⁴.
- Little is known about whether Family Pact-listed sites in this region actually offer the implant on-site or facilitate timely placement.

METHODOLOGY

- We gathered all of the Family Pact enrolled sites in the zip codes of San Bernardino and Riverside Counties
- The 131 sites were called, and given 3 chances to answer the call
- A single caller used a standardized, IRB approved script to simulate a 17-year old Family Pact patient seeking the etonogestrel contraceptive implant
- We recorded outcomes such as Family Pact acceptance, on-site implant availability, informal referral practices, preliminary visit requirements (2 visit), and telephone access barriers (hold times, transfers, etc).

RESULTS



- Among 131 sites listed on the Family Pact website, 8 did not answer after 3 attempts, 21 had incorrect or disconnected phone numbers, and 21 were reached but front desk staff were unable to provide definitive information on Family Pact participation or implant availability.
- 63 sites confirmed Family Pact participation (48.1%). Of these sites, 48 of them provided the etonogestrel implant on site.
- Only 10 of the 131 sites reported that the implant could be placed on site in one visit (See Figure 1).

DISCUSSION

- Although Family PACT is designed to reduce financial barriers to contraception, our findings demonstrate that coverage alone does not ensure meaningful access to the etonogestrel implant.
- Fewer than 8% of listed sites reported the ability to provide implant placement in a single visit, highlighting a substantial gap between program participation and timely contraceptive care.
- Barriers occurred at multiple levels, including inaccurate directory information, uncertainty among clinic staff, referral-dependent care, and requirements for preliminary visits.
- Improving access will require more than expanding contraceptive coverage. Maintaining accurate provider directories, improving staff knowledge of Family PACT services, and increasing same-day implant availability may help translate contraceptive coverage into actual, timely access.

REFERENCES

- California Department of Health Care Services, Office of Family Planning. *Family PACT Program Fact Sheet: An Overview*. 2024.
- Power to Decide. *Contraceptive Deserts 2025*. Washington, DC; 2025.
- U.S. Census Bureau. *QuickFacts: San Bernardino County, California; Riverside County, California*. Accessed July 23, 2026.
- Committee on Health Care for Underserved Women; Contraceptive Equity Expert Work Group. Increasing access to intrauterine devices and contraceptive implants: ACOG Committee Statement No. 5. *Obstet Gynecol*. 2023;141(4):866-872.
- Probst JC, Laditka SB, Wang JY, Johnson AO. Effects of residence and race on burden of travel for care. *BMC Health Serv Res*. 2007;7:40.

Figure 1. Family PACT acceptance, etonogestrel implant availability, referral pathways, and telephone access barriers among listed clinical sites.